Additional file 2: of Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial

Dermatopathology results. ÎąSMA alpha smooth muscle actin, Egr early growth response protein. (DOCX 15 kb)